An experimental Covid-19 remedy tablet referred to as molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen on this undated handout picture launched by Merck & Co Inc and obtained by Reuters Might 17, 2021. [Merck & Co Inc/Handout via Reuters]

Greece is bolstering its defenses towards Covid-19 and serving to ease the stress on the nationwide well being system with the introduction of dwelling deliveries of antiviral medication to high-risk sufferers, which started final Tuesday. These antivirals are prescribed within the early phases of the illness and their goal is to stop a critical deterioration.

Sufferers have proven a robust curiosity and already within the first three days of this system’s implementation, 384 functions had been submitted for the procurement of the medication. Most of those functions (359) had been authorised and the medication had been delivered by courier to the sufferers.

Nonetheless, specialists have been fast to emphasize that the brand new drug choices can by no means substitute the position of vaccines.

“The supply of recent remedies shouldn’t be a trigger for complacency about vaccinations,” Deputy Well being Minister Mina Gaga mentioned in feedback to Kathimerini.

“The vaccine stays our primary weapon within the combat towards the pandemic,” she mentioned, including that “new antiviral medication, if given within the first few days after analysis, will help older folks with critical well being issues who’re in danger for critical sickness.” 

Greece at the moment has 5,700 doses of Molnupiravir antivirals by Merck (MSD) out there and can obtain a further 25,000 doses as quickly because the drug is authorised by European regulators, which is predicted inside a month.

Eligible sufferers are these with a optimistic fast or molecular take a look at, whereas the appliance have to be submitted inside three days from the time of analysis.

It’s administered primarily to folks over the age of 65, these with a physique mass index over 35, transplant recipients, hemodialysis sufferers, most cancers sufferers and other people with continual kidney or liver illness, diabetes, hypertension, respiratory illness or coronary heart failure, and many others.


Leave a Reply

Your email address will not be published.